DBV Technologies Joins CAC Mid 60 and SBF 120 Indices

DBV Technologies, a late-stage biopharmaceutical company, has been admitted to the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review on March 12, 2026. These changes came into effect on March 23, 2026. The company's inclusion is expected to boost its visibility among French and European investment communities as it advances toward commercialization.

The CAC Mid 60 index comprises the 60 most actively traded mid-cap French companies, positioned just below the CAC Large 60. Meanwhile, the SBF 120 index includes companies from both the CAC Large 60 and CAC Mid 60, serving as a foundation for structured products and funds.

DBV Technologies specializes in developing treatments for food allergies through its proprietary VIASKIN® patch technology. The company focuses on using epicutaneous immunotherapy to help desensitize the immune system to allergens.